Table 5.
Measure of Substantial Cognitive Declineb | Serum 25(OH)D Level, nmol/L |
P Value for Linear Trend | |||
---|---|---|---|---|---|
≥75 | ≥50 to <75 | ≥25 to <50 | <25 | ||
MMSE | 1 [Reference] | 1.24 (0.88-1.63) | 1.09 (0.78-1.44) | 1.61 (1.19-2.01) | .02 |
Trails A | 1 [Reference] | 0.98 (0.57-1.55) | 1.18 (0.75-1.72) | 1.16 (0.65-1.72) | .44 |
Trails B | 1 [Reference] | 1.00 (0.74-1.24) | 1.11 (0.87-1.31) | 1.32 (1.03-1.51) | .05 |
Abbreviations: 25(OH)D, 25-hydroxyvitamin D; BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); CES-D, Center for Epidemiologic Studies Depression Scale30; MMSE, Mini-Mental State Examination29 (range, 0-30; higher score represents better function); Trails, Trail Making Tests (range, 0-300; higher score represents worse function).
Unless otherwise indicated, data are reported as relative risk (95% confidence interval). All analyses have been adjusted for age, sex, education, baseline cognitive score, season tested, alcohol consumption, current smoking status, depressive symptoms, body mass index, total energy intake, serum vitamin E level (alpha tocopherol), and impaired mobility plus potential mediators (stroke, hypertension, and diabetes).
Substantial cognitive decline was defined as 3 or more points on the MMSE and the worst 10% of cognitive decline or test discontinued for Trails A and B.